Core Viewpoint - As of February 6, 2026, Jiet Bio (688026) has seen a stock price increase of 2.56% from the previous week, closing at 18.4 yuan, with a total market capitalization of 2.583 billion yuan [1] Group 1: Company Stock Performance - Jiet Bio's stock reached a weekly high of 18.68 yuan and a low of 17.77 yuan during the week [1] - The company ranks 123rd out of 129 in the medical device sector and 4926th out of 5186 in the overall A-share market by market capitalization [1] Group 2: Share Buyback Announcement - The company announced a share buyback plan with a total fund of no less than 15 million yuan and no more than 30 million yuan, with a maximum buyback price of 25.32 yuan per share [1] - As of January 31, 2026, Jiet Bio has repurchased 272,799 shares, accounting for 0.19% of the total share capital, at an average price between 18.05 yuan and 18.43 yuan, totaling 4.9714 million yuan spent [1][3] Group 3: Legal Matters - Jiet Bio is involved in a lawsuit against Shenzhen Hesheng Medical Technology Co., regarding a contract dispute with a claim amount of 10,340,829 yuan [2] - The court ruled to terminate the contract and dismissed other claims, with the company fully provisioning for the prepaid amount as bad debt [2][3]

本周关注点 截至2026年2月6日收盘，祥生医疗（688358）报收于35.71元，较上周的36.62元下跌2.48%。本周，祥 生医疗2月2日盘中最高价报36.67元。2月2日盘中最低价报34.9元。祥生医疗当前最新总市值40.04亿 元，在医疗器械板块市值排名96/129，在两市A股市值排名4088/5186。 公司公告汇总 祥生医疗发布2025年前三季度权益分派实施公告，每股派发现金红利0.30元（含税），以公司总股本 112,125,613股为基数，合计派发现金红利33,637,683.90元。本次权益分派股权登记日为2026年2月11 日，除权（息）日为2026年2月12日，现金红利发放日为2026年2月12日。利润分配不派送红股、不转增 股本。部分股东红利由公司自行发放，其余通过中国证券登记结算有限责任公司上海分公司派发。股息 红利所得税依股东性质按规定执行。 公司公告汇总：祥生医疗每股派发现金红利0.30元（含税）。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

截至2026年2月6日收盘，心脉医疗（688016）报收于97.98元，较上周的95.03元上涨3.1%。本周，心脉 医疗2月5日盘中最高价报99.82元。2月2日盘中最低价报92.17元。心脉医疗当前最新总市值120.77亿 元，在医疗器械板块市值排名27/129，在两市A股市值排名1716/5186。 公司公告汇总 心脉医疗：关于获得医疗器械注册证的自愿性披露公告 近日，上海微创心脉医疗科技（集团）股份有限公司的全资子公司上海拓脉医疗科技有限公司获得国家 药品监督管理局颁发的聚乙烯醇栓塞微球医疗器械注册证，产品适用于富血管型实质性器官恶性肿瘤的 栓塞治疗。该产品为公司肿瘤介入治疗领域首款栓塞类产品，注册证有效期为2026年1月28日至2031年1 月27日。公司另有多个肿瘤介入产品已获批或在研。产品需取得生产许可证后方可上市销售，实际销售 情况受市场推广影响，目前无法预测对公司未来营业收入的影响。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 本周关注点 来自公司公告汇总：心脉医疗全资子公司获聚乙烯醇栓塞微球医疗器械注册证，用 ...

振德医疗用品股份有限公司于2026年2月4日收到天健会计师事务所出具的《关于变更项目质量复核人的 函》。因工作调整，原项目质量复核人郑传贤先生不再担任，由王文先生接任。王文先生自2011年起成 为中国注册会计师并从事上市公司审计，自2011年起在天健执业，2025年起为公司提供审计服务，近三 年签署或复核多家上市公司审计报告。其具备独立性，未因执业行为受过处罚。本次变更不影响公司 2025年度财务报表及内部控制审计工作的正常进行。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：振德医疗变更项目质量复核人，王文接任 公司公告汇总 截至2026年2月6日收盘，振德医疗（603301）报收于73.35元，较上周的68.77元上涨6.66%。本周，振 德医疗2月6日盘中最高价报73.8元。2月3日盘中最低价报66.42元。振德医疗当前最新总市值194.99亿 元，在医疗器械板块市值排名14/129，在两市A股市值排名1075/5186。 本周关注点 ...

| 指标 | 新华医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 93.3亿元 | 110.91亿元 | 43 128 | | 净资产 | 81.64亿元 | 38.15亿元 | 11 128 | | 净利润 | 4.34亿元 | 2.08亿元 | 15 128 | | 市盈率(动) | 16.11 | 91.01 | 4 128 | | 市净率 | 1.18 | ব | 10 128 | | 毛利率 | 25.11% | 50.55% | 113 128 | | 净利率 | 6.36% | 9.59% | 79 128 | | ROE | 5.65% | 0.42% | 48 128 | 证券之星消息，截至2026年2月6日收盘，新华医疗(600587)报收于15.38元，下跌0.45%，换手率 1.51%，成交量9.12万手，成交额1.41亿元。 2月6日的资金流向数据方面，主力资金净流出822.0万元，占总成交额5.82%，游资资金净流入532.41万 元，占总成交额3.77%，散户资金净流入289.59万元，占总成交额2.05%。 近5 ...

Core Viewpoint - The event "Guanghuo Xing Tianxia: Zhongshan Department Store Enters Shenzhen" aims to promote integration and collaboration between Zhongshan and Shenzhen, showcasing Zhongshan's products and culture to Shenzhen residents [1][3]. Group 1: Event Overview - The event was launched on February 7, supported by various government departments and aimed at enhancing the integration of Zhongshan and Shenzhen [1]. - The event features over 2,000 square meters of exhibition space with seven themed areas, showcasing more than 260 companies and their products [6]. Group 2: Government and Leadership Involvement - Zhongshan's leadership emphasized the importance of this event in promoting local products and fostering a sense of community between the two cities [3]. - Officials from both cities participated in the event, highlighting the collaborative efforts to enhance economic ties and consumer engagement [5][8]. Group 3: Product and Industry Highlights - The "Intelligent Manufacturing Zhongshan" section attracted over 150 manufacturing companies, presenting more than 400 products in fields such as robotics and medical devices [6]. - A variety of local agricultural products were showcased, including over 100 items from Zhongshan's agricultural sector [6]. Group 4: Economic Impact - The event facilitated 36 contracts between enterprises from both cities, with a total value of 3 billion yuan [8].

Core Viewpoint - The pharmaceutical retail market is transitioning towards high-quality development, with significant growth opportunities anticipated in various segments, including traditional Chinese medicine, medical devices, and innovative drugs [17][22][46]. Market Overview - The retail scale of China's physical pharmacies for January to November 2025 is projected to reach 557.7 billion yuan, showing a slight year-on-year decline of 0.8%. However, the cumulative scale for October and November is expected to be 108.7 billion yuan, reflecting a year-on-year growth of 4.0% [22][30]. - The pharmaceutical retail market is experiencing a recovery phase, driven by ongoing healthcare reforms and the optimization of market structures, which are expected to enhance the industry's long-term growth prospects [22][30]. Category Analysis - **Pharmaceuticals**: The cumulative scale for pharmaceuticals from January to November 2025 is estimated at 453.4 billion yuan, with a year-on-year growth of 0.4%. The sales scale for October and November is projected to be 88 billion yuan, with a year-on-year increase of 5.5% [29]. - **Traditional Chinese Medicine (TCM)**: The cumulative scale for TCM from January to November 2025 is expected to be 42.9 billion yuan, reflecting a year-on-year decline of 4.2%. However, November shows a month-on-month growth of 12.5% [30]. - **Medical Devices**: The cumulative scale for medical devices is projected to be 26.1 billion yuan, with a slight year-on-year decline of 0.4%. The sales scale for October and November is expected to show a year-on-year growth of 6.3% [37]. - **Health Products**: The cumulative scale for health products is anticipated to be 21 billion yuan, with a year-on-year decline of 15.7%. However, November shows signs of recovery with a month-on-month growth of 5.3% [34]. Investment Opportunities - The pharmaceutical sector is expected to benefit from a low valuation environment, with public funds showing low allocation to the sector. The anticipated recovery in macroeconomic factors and the demand for major products are expected to drive growth in the industry [15]. - The innovative drug sector is transitioning from quantity to quality, with a focus on differentiated products and internationalization. Companies with strong pipelines and the ability to deliver profits are recommended for investment [15][46]. - The medical device market is witnessing a recovery in bidding volumes, with ongoing updates and international expansion opportunities. Companies focusing on innovation and product upgrades are expected to perform well [46]. Specific Product Trends - **Top Chemical Drugs**: In October and November 2025, the top 20 chemical drug categories accounted for 78.3% and 80.0% of the market share, respectively, with significant growth in categories such as anti-tumor drugs and systemic antiviral drugs [40][41]. - **Top Traditional Chinese Medicine Products**: The market share for TCM in November reached 86.4%, with notable growth in cold medications and cough remedies [44][45]. Conclusion - The pharmaceutical retail market is poised for a significant transformation, with various segments showing potential for growth. The ongoing reforms and market dynamics are expected to create a favorable environment for investment in the pharmaceutical and healthcare sectors [22][30][46].

Core Viewpoint - Three listed companies have been named by the China Securities Regulatory Commission (CSRC) for investigations, indicating a tightening regulatory environment with a "zero tolerance" approach towards misconduct in the capital market [4][20]. Group 1: Company Investigations - Ayhuilong and Tiansheng New Materials have been initiated for investigation due to misleading statements and information disclosure violations, respectively [1][7]. - Ayhuilong's investigation stems from a strategic cooperation framework agreement that was found to contain misleading descriptions about its partner, Brain Machine Star Chain [10][11]. - Tiansheng New Materials' investigation is less specific, with the company announcing it is under investigation for information disclosure violations [7][10]. Group 2: Administrative Penalties - ST Funeng has received an administrative penalty due to financial fraud by its former subsidiary, resulting in a profit inflation of approximately 35.8 million yuan in 2020 [15][16]. - The penalty imposed on ST Funeng is 6.5 million yuan, which is relatively low compared to other penalties in the market, reflecting the lesser severity of the fraud and the fact that the subsidiary has been divested [18][19]. - ST Funeng is the 11th company to receive an administrative penalty in 2026, highlighting a trend of increasing regulatory actions against listed companies [19]. Group 3: Regulatory Environment - Since the beginning of 2026, there have been eight companies or their controlling persons under investigation, indicating an average of one investigation every five days [2][3][10]. - The regulatory actions are part of a broader strategy to enhance oversight, focusing on specific issues such as misleading statements and significant omissions in disclosures [13][20]. - The speed of investigations and penalties is increasing, suggesting a systematic effort to reshape the market's overall ecosystem [20].

Core Viewpoint - The article highlights the increasing regulatory scrutiny in the Chinese capital market, with multiple companies facing investigations and penalties for misleading statements and financial misconduct, indicating a "zero tolerance" approach by regulators [2][7]. Group 1: Company Investigations - Three listed companies, including Yahui Long and Tian Sheng New Materials, have been named by the China Securities Regulatory Commission (CSRC) for investigations, with Yahui Long's case linked to misleading statements regarding a strategic cooperation framework related to brain-computer interface technology [1][4]. - Tian Sheng New Materials is under investigation for suspected violations of information disclosure laws, although specific details have not been disclosed [1][4]. - As of February 6, 2026, a total of eight listed companies or their controlling shareholders have been investigated, with an average of one company being investigated every five days [5][7]. Group 2: Administrative Penalties - ST Fuheng has received an administrative penalty due to financial fraud by its subsidiary, which inflated profits by approximately 35.8 million yuan in 2020 through fictitious procurement transactions [9][11]. - The penalty imposed on ST Fuheng amounts to 6.5 million yuan, which is relatively low compared to other penalties in the market, reflecting the lesser severity of the fraud and the fact that the involved subsidiary has been divested [9][11]. - ST Fuheng is the 11th company to receive an administrative penalty in 2026, indicating a trend of increasing regulatory actions against financial misconduct [8][11]. Group 3: Regulatory Trends - The regulatory environment is shifting towards a more stringent approach, with a focus on specific issues such as misleading statements and significant omissions in information disclosure [7][12]. - The CSRC's speed in initiating investigations has increased, with a notable rise in the number of companies being investigated for various types of misconduct, including market manipulation and financial fraud [7][12]. - The article emphasizes that the regulatory framework is evolving to address systemic issues in corporate governance, aiming to reshape the overall market ecosystem [12].

Core Viewpoint - The event "Guanghuo Xing Tianxia: Zhongshan Department Store Enters Shenzhen" aims to promote the integration of Shenzhen and Zhongshan, showcasing local products and facilitating business cooperation with a total of 36 signed projects worth 3 billion yuan [1][4]. Group 1: Event Overview - The event is hosted by the Zhongshan Municipal Government and focuses on deepening the integration of Shenzhen and Zhongshan [4]. - It features a variety of activities, including a showcase of Zhongshan's manufacturing capabilities, cultural attractions, and consumer experiences [4]. Group 2: Key Highlights - The event includes seven thematic sections, such as "Charming Zhongshan," which highlights urban planning, business environment, and public services [4]. - "Smart Manufacturing Zhongshan" showcases over 400 products from more than 150 manufacturing companies, including robots and medical devices [4]. - The "Culinary Zhongshan" section features over 100 local agricultural products, with interactive experiences like tasting and live cooking demonstrations [4][5]. Group 3: Economic Impact - A total of 36 procurement projects were signed during the event, amounting to 3 billion yuan, indicating strong economic collaboration between the two cities [1]. - The event also promotes tourism with the introduction of 2 million yuan in cultural tourism consumption vouchers [4]. Group 4: Cultural and Community Engagement - The event includes traditional performances and showcases local heritage, enhancing community engagement and cultural exchange [5]. - Online and offline promotional activities are integrated, including a live streaming session to foster collaboration between artisans from both cities [5].